Clinical Trial Update: Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating different silymarin dosages versus placebo for lowering elevated liver enzymes in drug-induced liver injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-induced Liver Injury

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: Prof. Dr. Frank Behrens | Conditions: Drug-induced Liver Injury | Phase 2, Phase 3 | Status: COMPLETED